Early Access vs Clinical Trials: What Every Patient Needs to Understand
Many patients have heard of clinical trials, but fewer know about Early Access (Expanded Access/Compassionate Use) programs. While both may provide access to investigational treatments, they serve very different purposes—and understanding the difference can help patients explore all available options and ask the right questions. In our latest article, we explain how clinical trials and Early Access programs work, who may be eligible, and when each pathway may be appropriate. FDA Approves a New Treatment Option for Advanced Breast Cancer
The FDA has approved a new targeted therapy for adults with HR-positive, HER2-negative advanced or metastatic breast cancer whose disease progressed after endocrine therapy. In a clinical trial, the treatment significantly delayed cancer progression compared with standard therapy, offering a new option for patients with limited treatment choices.
Learn more What Doctors Don't Always Tell You About Experimental Treatments
When standard treatment options run out, many patients assume there is nothing left to try. But "no more options" often means no more options at that particular hospital. In this article, we explain how to search for clinical trials more effectively, why eligibility isn't always as final as it seems, and what other pathways may still be available when a trial isn't an option. ESMO Congress Highlights New Hope for Gastrointestinal Cancer Patients
At the ESMO Gastrointestinal Cancers Congress 2026, researchers presented promising advances in the treatment of pancreatic and colorectal cancers. New targeted therapies against KRAS mutations, improved immunotherapy strategies, and next-generation antibody-drug conjugates are expanding treatment options and moving the field closer to more personalized care for patients with gastrointestinal cancers.
Learn more Patients Can't Join Trials They Don't Understand
What is informed consent? Can I leave a study at any time? Is it safe to participate in a clinical trial? These are some of the most common questions patients ask—and too often, the answers aren't easy to find. That's why our partner company, Cromos Pharma, launched a new library of short patient education videos designed to explain clinical trial participation in plain language. Understanding every possible pathway matters.
Learn more Phase III Study Shows Major Survival Benefit for Multiple Myeloma Patients
A Phase III clinical trial has shown that combining two immunotherapies significantly improved outcomes for people with relapsed or refractory multiple myeloma. One treatment combination reduced the risk of death by 62% and significantly delayed disease progression compared with current standard treatment options. The findings could help bring these therapies into earlier stages of treatment, expanding options for patients living with multiple myeloma.
Learn more Immunotherapy May Help Some Rectal Cancer Patients Avoid Surgery
A Phase II clinical trial has shown that the immunotherapy Jemperli (dostarlimab) produced sustained complete responses in some patients with a specific type of locally advanced rectal cancer. If approved, the treatment could allow some people to avoid chemotherapy, radiation, and surgery—offering the possibility of effective cancer treatment while preserving quality of life. The results are now being submitted to health authorities for regulatory review.
Learn more Could Sitting Less Help Lower Cancer Risk?
A new study suggests that sitting for long periods without a break may be linked to a higher risk of dying from cancer. Researchers found that getting up and moving more often, even for light activity, could help improve long-term health.